Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study

G. F. Gensini, A. M. Gori, B. Dilaghi, C. Rostagno, A. Gaw, L. M. Blanco-Colio, E. De Teresa, J. Egido, C. Farsang, L. A. Leiter, P. Martineau, A. Nozza, A. Langer

Research output: Contribution to journalArticle

Abstract

Background: Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events that may add prognostic information. Statin treatment is associated with significant reductions in CRP concentrations, which appear to be unrelated to the magnitude of LDL-cholesterol reduction. We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk. Methods: ACTFAST was a 12 week, prospective, multicenter, open-label trial in which high-risk subjects were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/d) based on LDL-C and status of statin use at screening (1345 statin-free [SF] and 772 previously statin-treated [ST]). Results: At baseline, ST subjects had significantly lower hsCRP levels than SF subjects (ST group 2.31, 95% CI 2.15, 2.48 mg/L vs. SF group 3.16, 95% CI 2.98, 3.34 mg/L, p <0.05). In the SF group, atorvastatin 10 to 80 mg significantly (p <0.01) reduced hsCRP levels in a dose dependent-manner. In ST group, additional hsCRP reductions were observed over the statin used at baseline, which were not dose-dependent. Atorvastatin significantly decreased hsCRP concentrations in subjects with or without diabetes or the metabolic syndrome. Conclusions: Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. This reduction was observed in both SF and ST groups and was independent of the presence of metabolic syndrome and/or diabetes. The beneficial effect of atorvastatin was evident at 6 weeks, supporting the practice of early introduction of higher doses of atorvastatin in high-risk patients.

Original languageEnglish
Pages (from-to)257-264
Number of pages8
JournalInternational Journal of Cardiology
Volume142
Issue number3
DOIs
Publication statusPublished - Jul 23 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
C-Reactive Protein
Atorvastatin Calcium
LDL Cholesterol

Keywords

  • Atorvastatin
  • C-reactive protein (hsCRP)
  • Coronary artery disease
  • Dyslipidemia
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Effect of atorvastatin on circulating hsCRP concentrations : A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. / Gensini, G. F.; Gori, A. M.; Dilaghi, B.; Rostagno, C.; Gaw, A.; Blanco-Colio, L. M.; De Teresa, E.; Egido, J.; Farsang, C.; Leiter, L. A.; Martineau, P.; Nozza, A.; Langer, A.

In: International Journal of Cardiology, Vol. 142, No. 3, 23.07.2010, p. 257-264.

Research output: Contribution to journalArticle

Gensini, GF, Gori, AM, Dilaghi, B, Rostagno, C, Gaw, A, Blanco-Colio, LM, De Teresa, E, Egido, J, Farsang, C, Leiter, LA, Martineau, P, Nozza, A & Langer, A 2010, 'Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study', International Journal of Cardiology, vol. 142, no. 3, pp. 257-264. https://doi.org/10.1016/j.ijcard.2008.12.213
Gensini, G. F. ; Gori, A. M. ; Dilaghi, B. ; Rostagno, C. ; Gaw, A. ; Blanco-Colio, L. M. ; De Teresa, E. ; Egido, J. ; Farsang, C. ; Leiter, L. A. ; Martineau, P. ; Nozza, A. ; Langer, A. / Effect of atorvastatin on circulating hsCRP concentrations : A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. In: International Journal of Cardiology. 2010 ; Vol. 142, No. 3. pp. 257-264.
@article{5e8834e4e1c74066b8bfb3788bbd977c,
title = "Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study",
abstract = "Background: Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events that may add prognostic information. Statin treatment is associated with significant reductions in CRP concentrations, which appear to be unrelated to the magnitude of LDL-cholesterol reduction. We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk. Methods: ACTFAST was a 12 week, prospective, multicenter, open-label trial in which high-risk subjects were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/d) based on LDL-C and status of statin use at screening (1345 statin-free [SF] and 772 previously statin-treated [ST]). Results: At baseline, ST subjects had significantly lower hsCRP levels than SF subjects (ST group 2.31, 95{\%} CI 2.15, 2.48 mg/L vs. SF group 3.16, 95{\%} CI 2.98, 3.34 mg/L, p <0.05). In the SF group, atorvastatin 10 to 80 mg significantly (p <0.01) reduced hsCRP levels in a dose dependent-manner. In ST group, additional hsCRP reductions were observed over the statin used at baseline, which were not dose-dependent. Atorvastatin significantly decreased hsCRP concentrations in subjects with or without diabetes or the metabolic syndrome. Conclusions: Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. This reduction was observed in both SF and ST groups and was independent of the presence of metabolic syndrome and/or diabetes. The beneficial effect of atorvastatin was evident at 6 weeks, supporting the practice of early introduction of higher doses of atorvastatin in high-risk patients.",
keywords = "Atorvastatin, C-reactive protein (hsCRP), Coronary artery disease, Dyslipidemia, Statins",
author = "Gensini, {G. F.} and Gori, {A. M.} and B. Dilaghi and C. Rostagno and A. Gaw and Blanco-Colio, {L. M.} and {De Teresa}, E. and J. Egido and C. Farsang and Leiter, {L. A.} and P. Martineau and A. Nozza and A. Langer",
year = "2010",
month = "7",
day = "23",
doi = "10.1016/j.ijcard.2008.12.213",
language = "English",
volume = "142",
pages = "257--264",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Effect of atorvastatin on circulating hsCRP concentrations

T2 - A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study

AU - Gensini, G. F.

AU - Gori, A. M.

AU - Dilaghi, B.

AU - Rostagno, C.

AU - Gaw, A.

AU - Blanco-Colio, L. M.

AU - De Teresa, E.

AU - Egido, J.

AU - Farsang, C.

AU - Leiter, L. A.

AU - Martineau, P.

AU - Nozza, A.

AU - Langer, A.

PY - 2010/7/23

Y1 - 2010/7/23

N2 - Background: Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events that may add prognostic information. Statin treatment is associated with significant reductions in CRP concentrations, which appear to be unrelated to the magnitude of LDL-cholesterol reduction. We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk. Methods: ACTFAST was a 12 week, prospective, multicenter, open-label trial in which high-risk subjects were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/d) based on LDL-C and status of statin use at screening (1345 statin-free [SF] and 772 previously statin-treated [ST]). Results: At baseline, ST subjects had significantly lower hsCRP levels than SF subjects (ST group 2.31, 95% CI 2.15, 2.48 mg/L vs. SF group 3.16, 95% CI 2.98, 3.34 mg/L, p <0.05). In the SF group, atorvastatin 10 to 80 mg significantly (p <0.01) reduced hsCRP levels in a dose dependent-manner. In ST group, additional hsCRP reductions were observed over the statin used at baseline, which were not dose-dependent. Atorvastatin significantly decreased hsCRP concentrations in subjects with or without diabetes or the metabolic syndrome. Conclusions: Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. This reduction was observed in both SF and ST groups and was independent of the presence of metabolic syndrome and/or diabetes. The beneficial effect of atorvastatin was evident at 6 weeks, supporting the practice of early introduction of higher doses of atorvastatin in high-risk patients.

AB - Background: Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events that may add prognostic information. Statin treatment is associated with significant reductions in CRP concentrations, which appear to be unrelated to the magnitude of LDL-cholesterol reduction. We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk. Methods: ACTFAST was a 12 week, prospective, multicenter, open-label trial in which high-risk subjects were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/d) based on LDL-C and status of statin use at screening (1345 statin-free [SF] and 772 previously statin-treated [ST]). Results: At baseline, ST subjects had significantly lower hsCRP levels than SF subjects (ST group 2.31, 95% CI 2.15, 2.48 mg/L vs. SF group 3.16, 95% CI 2.98, 3.34 mg/L, p <0.05). In the SF group, atorvastatin 10 to 80 mg significantly (p <0.01) reduced hsCRP levels in a dose dependent-manner. In ST group, additional hsCRP reductions were observed over the statin used at baseline, which were not dose-dependent. Atorvastatin significantly decreased hsCRP concentrations in subjects with or without diabetes or the metabolic syndrome. Conclusions: Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. This reduction was observed in both SF and ST groups and was independent of the presence of metabolic syndrome and/or diabetes. The beneficial effect of atorvastatin was evident at 6 weeks, supporting the practice of early introduction of higher doses of atorvastatin in high-risk patients.

KW - Atorvastatin

KW - C-reactive protein (hsCRP)

KW - Coronary artery disease

KW - Dyslipidemia

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=77955756190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955756190&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2008.12.213

DO - 10.1016/j.ijcard.2008.12.213

M3 - Article

C2 - 19217176

AN - SCOPUS:77955756190

VL - 142

SP - 257

EP - 264

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -